Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden\nhealthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial\ntreatments. Approval of a biosimilar product relies on the demonstration of ââ?¬Å?comparabilityââ?¬Â or ââ?¬Å?no clinically meaningful\ndifferencesââ?¬Â as compared to its reference biologic product. Biosimilar products for erythropoietin, granulocyte colonystimulating\nfactor, trastuzumab, and rituximab are already available, and the regulatory processes in various countries\nare constantly evolving. It is important that oncologists be familiar with the potential issues surrounding the clinical\nuse of biosimilar products. In this review article, we provide background information about biosimilar products and\ntheir regulatory approval processes, followed by a discussion of individual biosimilar drugs.
Loading....